Decoy Therapeutics DCOY
NASDAQ DCOY
$3.26 -0.02 (-0.62%)
As of: Aug 21, 2026 · 11:51 AM EDT

Decoy Therapeutics (DCOY) Current Deferred Revenue (2014 - 2026)

Decoy Therapeutics (DCOY) posted quarterly Current Deferred Revenue of $3.2 million for Q1 2026, little changed quarter-over-quarter from $3.2 million in Q4 2025.

Decoy Therapeutics (DCOY) Current Deferred Revenue (2014 - 2026) Analysis & Trends

Decoy Therapeutics (DCOY) has reported Current Deferred Revenue for 8 consecutive years, with $3.2 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Current Deferred Revenue changed N/A year-over-year to $3.2 million; the TTM figure through Mar 2026 stood at $3.2 million (changed N/A YoY), while the FY2025 annual figure was $3.2 million, changed N/A from the prior year.
  • Current Deferred Revenue was little changed at $3.2 million in Q1 2026 per DCOY's latest filing, from $3.2 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $3.2 million in Q4 2025 and bottomed at $3.2 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 139.79 Bn 131.94 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 86.74 Bn 78.74 Bn 3.93 Bn
3 Argenx Se 65.48 Bn 60.29 Bn 1.37 Bn
4 Moderna 59.32 Bn 54.18 Bn 52.00 Mn
5 BeOne Medicines 42.08 Bn 36.98 Bn 1.53 Bn
6 Alnylam Pharmaceuticals 31.81 Bn 28.50 Bn 992.69 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn
8 Insmed 27.56 Bn 26.40 Bn 358.27 Mn
9 Royalty Pharma 27.29 Bn 26.45 Bn -
10 Decoy Therapeutics 1.73 Mn 1.73 Mn -

Historic Data

Download Data
DateValue
Jun 30, 2026 3.00 Mn
Mar 31, 2026 3.23 Mn
Dec 31, 2025 3.23 Mn
Dec 31, 2019 1.00 Mn
Sep 30, 2019 2.00 Mn
Dec 31, 2018 4.10 Mn
Sep 30, 2018 53,919.00
Mar 31, 2018 58,821.00
Dec 31, 2017 58,821.00
Sep 30, 2017 58,821.00
Mar 31, 2017 7,579.00
Dec 31, 2016 21,095.00
Sep 30, 2016 25,351.00
Jun 30, 2016 65,115.00
Mar 31, 2016 24,174.00
Sep 30, 2015 21,881.00
Jun 30, 2015 21,881.00
Mar 31, 2015 21,881.00
Dec 31, 2014 21,881.00